The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A growing number of prostate cancer experts argue that calling the lowest-risk prostate cancer “cancer” does more harm than good. A UCLA-led study found removing the cancer label could dramatically reduce overtreatment and encourage more men to get screened, potentially leading to significantly fewer deaths from aggressive prostate cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Pasritamig-based immunotherapy regimen shows 73% PSA response rate in advanced prostate cancer in phase I study

At the recommended regimen, 73% of patients receiving a pasritamig and JNJ-9401 combination, two bispecific antibodies designed to work together to drive the body’s immune response against advanced prostate cancer, achieved reductions of at least 50% in prostate-specific antigen, according to the results of a first-in-human phase I study. 
Clinical Roundup

Perioperative apalutamide reduces risk of death and metastasis in high-risk localized or locally advanced prostate cancer, study finds

An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.
Clinical Roundup

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account